Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - prednisolone sodium phosphate, quantity: 6.72 mg (equivalent: prednisolone, qty 5 mg) - suppository, moulded - excipient ingredients: hard fat - indications as at 01 jan 1991 : predsol suppositories are indicated for the treatment of haemorrhagic and granular proctitis, post-radiation proctitis and rectal complication of crohn's disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amoxicillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amoxicillin -

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - perhexiline maleate, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; purified talc; sucrose; lactose monohydrate - to reduce the frequency of moderate to severe attacks of angina pectoris due to coronary artery disease in patients who have not responded to other conventional therapy or in whom such therapy may be contra-indicated. note: because of the serious nature of potential side effects, perhexiline maleate should be reserved for use in patients with intractable angina who are refactory or intolerant to other agents and who are not suitable canditates for coronary bypass surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - triamcinolone acetonide, quantity: 40 mg/ml - injection, suspension - excipient ingredients: benzyl alcohol; sodium chloride; polysorbate 80; carmellose sodium; water for injections; sodium hydroxide; hydrochloric acid - intramuscular: the intramuscular administration of kenacort-a 40 (sterile triamcinolone acetonide suspension usp) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. intramuscular administration is particularly valuable in such conditions where oral corticosteroid therapy is not feasible. intra-articular: kenacort-a 40 injection is indicated for intra-articular or intrasynovial administration and for injections into tendon sheaths as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute non-specific tenosynovitis; post-traumatic osteoarthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - ethambutol hydrochloride, quantity: 100 mg - tablet, film coated - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); sucrose; gelatin; stearic acid; magnesium stearate; quinoline yellow; purified water; purified talc; shellac; industrial methylated spirit; povidone; acetylated monoglycerides - indications as at 04 jan 2002 : oral administation : myambutol is indicated for the treatment of pulmonary tuberculosis, as shown by a large number of studies by investigators throughout the world. it has also been used successfully in cases of primary tuberculosis and extrapulmonary forms of tuberculosis, including miliary tuberculosis, tuberculois meningitis, tuberculosis of bones and joints, genitourinary tuberculosis, tuberculous of the shin and tuberculous eye diseases. it should not be used as the sole antituberculosis drug, but should be used in conjuction with at least one other antituberculosis drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculosis therapy, i.e. initial treatment, the most frequently used regimens have included three of the following drugs - myambutol, isoniazid, rifampicin and streptomycin - for the first 2-4 mo

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - minocycline hydrochloride dihydrate, quantity: 53.985 mg (equivalent: minocycline, qty 50 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; sodium starch glycollate; povidone; sorbitol; microcrystalline cellulose; stearic acid; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf; quinoline yellow; light liquid paraffin; sodium lauryl sulfate - indications as at 12 november 2003 : minocycline may be used for the treatment of infections caused by any of the following organisms provided that they have been shown by bacteriological testing to be susceptible to minocycline: escherichia coli, enterobacter aerogenes, haemophilus influenzae, klebsiella and proteus. it may also be used in the treatment of infections due to streptococcus pyogenes (group a beta-haemolytic) and streptococcus faecalis but because a large proportion of these organisms are resistant to tetracyclines, minocycline should be used only if the orgaisms have been shown to be definitely sensitive. tetracyclines, including minocycline, are not the drugs of choice in the treatment of staphylococcal infections. minocycline may be considered for the treatment of such infections only if other suitable agents are not available and the organism has been shown to be sensitive to minocycline. minocycline may be used in the treatment of tetracycline-resistant acne.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - digoxin, quantity: 50 microgram/ml - oral liquid - excipient ingredients: methyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; sucrose; citric acid; ethanol; propylene glycol; quinoline yellow; purified water; flavour - indications as at 26 july 2000 : congestive heart failure - lanoxin is useful regardless of whether the failure is predominantly of the left or right ventricle, or involves both sides of the heart. it is particularly useful in heart failure resulting from chronic overload (hypertension, valvular lesions, atherosclerotic heart disease) in which the supply of energy is not impaired. lanoxin does not cause major benefit in situations in which the metabolic energy supply is compromised as in thyrotoxicosis, hypoxia, and severe thiamine deficiency. atrial fibrillation - because lanoxin depresses conduction in the atrioventricular bundle, producing a slower ventricular beat, it is valuable in atrial fibrillation. it will frequently convert atrial flutter into fibrillation and, upon withdrawal of the drug, normal sinus rhythm may be restored. paroxysmal atrial tachycardia - lanoxin may relieve or prevent an attack, but its use in paroxysmal ventricular tachycardia is dangerous.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - atropine sulfate monohydrate, quantity: 9.9737 mg/ml - eye drops, solution - excipient ingredients: boric acid; disodium edetate; benzalkonium chloride; hypromellose; water for injections - indications as at 06 august 1999: atropt eye drops are indicated where it is necessary to dilate the pupil and paralyse accomodation.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - megestrol acetate -